Puthanveetil Prasanth, Chen Shali, Feng Biao, Gautam Anirudh, Chakrabarti Subrata
Department of Pathology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
J Cell Mol Med. 2015 Jun;19(6):1418-25. doi: 10.1111/jcmm.12576. Epub 2015 Mar 19.
To examine whether the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is altered in the endothelial cells in response to glucose and the significance of such alteration. We incubated human umbilical vein endothelial cells with media containing various glucose levels. We found an increase in MALAT1 expression peaking after 12 hrs of incubation in high glucose. This increase was associated with parallel increase in serum amyloid antigen 3 (SAA3), an inflammatory ligand and target of MALAT1 and was further accompanied by increase in mRNAs and proteins of inflammatory mediators, tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). Renal tissue from the diabetic animals showed similar changes. Such cellular alterations were prevented following MALAT1 specific siRNA transfection. Results of this study indicate that LncRNA MALAT1 regulates glucose-induced up-regulation of inflammatory mediators IL-6 and TNF-α through activation of SAA3. Identification of such novel mechanism may lead to the development of RNA-based therapeutics targeting MALAT1 for diabetes-induced micro and macro vascular complications.
为了研究长链非编码RNA(lncRNA)转移相关肺腺癌转录本1(MALAT1)在内皮细胞中对葡萄糖的响应是否发生改变以及这种改变的意义。我们用含有不同葡萄糖水平的培养基培养人脐静脉内皮细胞。我们发现,在高糖环境中培养12小时后,MALAT1表达增加并达到峰值。这种增加与炎症配体及MALAT1的靶标血清淀粉样抗原3(SAA3)的平行增加相关,并且进一步伴随着炎症介质肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)的mRNA及蛋白质增加。糖尿病动物的肾组织显示出类似变化。在转染MALAT1特异性siRNA后,这种细胞改变得到了预防。本研究结果表明,LncRNA MALAT1通过激活SAA3来调节葡萄糖诱导的炎症介质IL-6和TNF-α的上调。鉴定这种新机制可能会导致开发针对MALAT1的基于RNA的疗法,用于治疗糖尿病引起的微血管和大血管并发症。